Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NPX-5 in psilocybin-assisted psychotherapy PAP for treating adjustment disorder related to cancer diagnosis. This Phase IIb randomized, double-blind study compares three doses of NPX-5 25 mg, 10 mg, and 1 mg in adults aged 18 to 80 who experience anxiety after a stressful cancer diagnosis. The study aims to generate knowledge that could support new treatments for anxiety and depression following such events. Participants are randomly assigned to receive one of three NPX-5 doses during an approximately 8-hour PAP dosing session on Day 14. Those who do not respond by Week 10 may be offered a second PAP cycle at the 25 mg dose. A maximum of two PAP cycles can be administered. The study combines in-person clinic visits and telehealth sessions, including screening, preparation, dosing, integration, and follow-up visits, with remote and in-person therapy sessions involving a primary therapist and optionally a sitter or secondary therapist. Participants undergo screening and baseline assessments before treatment. They complete preparation sessions before dosing and attend follow-up visits at Weeks 4, 6, and 10, plus a final safety and tolerability assessment three months after the last PAP cycle. Researchers measure anxiety severity using the Hamilton Anxiety Rating Scale, monitor adverse events, and assess suicidality with the Sheehan Suicide Tracking Scale throughout the study. The total participation period includes up to two treatment cycles and long-term follow-up.